Company Expects to Submit PowerLook Tomo Detection Version 2.0 for FDA Approval Shortly

Submission to be Based on Promising Results from Pivotal Clinical Reader Study

Conference call today at 4:30 p.m. ET


NASHUA, N.H. (May 14, 2018) – iCAD, Inc. (NASDAQ: ICAD), a global medical technology leader
providing innovative cancer detection and therapy solutions, today reported
financial results for the first quarter ended March 31, 2018.


First Quarter 2018 Financial Highlights:

  Total revenue of $6.3 million, down 7% year-over-year

  Gross profit of $4.5 million, or 71%

GAAP Net Loss of $(3.3) million, or $(0.20) per

Non-GAAP Adjusted EBITDA loss of $(2.4) million

View Webcast
Full Results